News >

Expert Discusses Optimizing Sequence of Non-Hormonal Therapy in mCRPC

Gina Columbus @ginacolumbusonc
Published: Monday, Oct 02, 2017

Daniel J. George, MD

Daniel J. George, MD
While hormonal-based therapies are a standard component of the treatment landscape of metastatic castration-resistant prostate cancer (mCRPC), other agents are available for first-line use that have the potential to improve outcomes, explains Daniel J. George, MD.

on Genitourinary Cancers. In an interview during the event, he spoke to the major questions practitioners are asking regarding optimizing upfront therapy for patients with mCRPC.

OncLive: What did you highlight in your presentation on mCRPC?

George: For advanced prostate cancer, particularly mCRPC, there has been a tremendous amount of progress in the last 7 years. With 5 new agents now approved, all demonstrating improvement in overall survival coupled with our historical docetaxel chemotherapy, we now have tremendous flexibility and variety in how we can treat and sequence patients with mCRPC. 

You mentioned earlier that this poses a challenge. In what way?

The problem with all of that is with that variation and flexibility comes perhaps the inability to recognize when different kinds of sequences are [available]. There is a tendency to form a habit of treating everybody the same. We do this partly because in prostate cancer, for the most part, hormonal therapy is the mainstay of treatment for patients who relapse on local therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Medical Crossfire®: Treating MS in the Modern Era: Right Patient, Right Treatment, Right TimeApr 20, 20201.5
Publication Bottom Border
Border Publication